Key result
Conversion to TAC-mTOR immunosuppression after kidney-pancreas transplantation significantly reduced the risk of BK viremia compared to maintenance on TAC-MMF (HR for MMF vs mTOR 12.27, P=0.02).
Why the study?
Does conversion to TAC-mTOR immunosuppression reduce the incidence of BK and CMV viremia in kidney-pancreas transplant recipients?
Cohort (n=79)
No
Does conversion to TAC-mTOR immunosuppression reduce the incidence of BK and CMV viremia in kidney-pancreas transplant recipients?
Hazard Ratio: 12.27
p-value: p=0.02
Conversion from TAC-MMF to TAC-mTOR immunosuppression after kidney-pancreas transplantation significantly reduces the incidence of BK and CMV viremia without increasing rejection risk.
No takes yet. Share an insight, caveat, or question.
May support mTOR conversion to lower BK viremia after kidney-pancreas transplant; hypothesis-generating and requires RCT confirmation.
Knight et al. (2018) conducted a cohort in Kidney-pancreas transplantation (n=79). Tacrolimus/mTOR inhibitor (TAC-mTOR) vs. Tacrolimus/mycophenolate mofetil (TAC-MMF) was evaluated on BK viremia (HR 12.27, p=0.02). Conversion to TAC-mTOR immunosuppression after kidney-pancreas transplantation significantly reduced the risk of BK viremia compared to maintenance on TAC-MMF (HR for MMF vs mTOR 12.27, P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: